公开(公告)号：US11274080B2

公开(公告)日：2022-03-15

申请号：US16737366

申请日：2020-01-08

Applicant: NOVARTIS AG

Inventor： Gebhard Thoma

IPC: C07D213/74 ,  C07D401/12 ,  A61K31/444

Abstract: The present invention describes novel diamino pyridine derivatives exhibiting JAK modulating properties. The present invention also relates to pharmaceutical compositions comprising these novel compounds, methods of using said compounds in the treatment of various diseases and disorders being susceptible to JAK modulation, and processes for preparing the compounds described hereinafter.

公开(公告)号：US12157737B2

公开(公告)日：2024-12-03

申请号：US18319585

申请日：2023-05-18

Applicant: NOVARTIS AG

Inventor： Mallesh Bushaboina ,  Xin Chen ,  Atwood Kim Cheung ,  Andrew James Culshaw ,  Timothy Brian Hurley ,  Nancy Labbe-Giguere ,  Wolfgang Miltz ,  David Orain ,  Tajesh Patel ,  Srinivasan Rajagopalan ,  Till Roehn ,  David Andrew Sandham ,  Gebhard Thoma ,  Ritesh Bhanudasji Tichkule ,  Rudolf Wälchli

IPC: A61K31/438 ,  A61K31/506 ,  A61K45/06 ,  C07D471/10 ,  C07D519/00

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; wherein R1 R2, R4 and X1 are defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

公开(公告)号：US11932630B2

公开(公告)日：2024-03-19

申请号：US17716423

申请日：2022-04-08

Applicant: NOVARTIS AG

Inventor： Andreas Kordikowski ,  Yugang Liu ,  Rainer Martin Lüönd ,  Christian Markert ,  Wolfgang Miltz ,  Till Roehn ,  Carsten Spanka ,  Gebhard Thoma ,  Tian Xie

IPC: C07D413/10 ,  A61K31/41 ,  A61K31/4245 ,  A61K31/436 ,  A61K31/4439 ,  A61K45/06 ,  C07D257/04 ,  C07D401/12 ,  C07D401/14 ,  C07D413/14 ,  C07D471/04

CPC classification number: C07D413/10 ,  A61K31/41 ,  A61K31/4245 ,  A61K31/436 ,  A61K31/4439 ,  A61K45/06 ,  C07D257/04 ,  C07D401/12 ,  C07D401/14 ,  C07D413/14 ,  C07D471/04

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof,




a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

公开(公告)号：US11708366B2

公开(公告)日：2023-07-25

申请号：US17400458

申请日：2021-08-12

Applicant: Novartis AG

Inventor： Mallesh Bushaboina ,  Xin Chen ,  Atwood Kim Cheung ,  Andrew James Culshaw ,  Timothy Brian Hurley ,  Nancy Labbe-Giguere ,  Wolfgang Miltz ,  David Orain ,  Tajesh Patel ,  Srinivasan Rajagopalan ,  Till Roehn ,  David Andrew Sandham ,  Gebhard Thoma ,  Ritesh Bhanudasji Tichkule ,  Rudolf Wälchli

IPC: C07D471/10 ,  A61K31/438 ,  A61K45/06 ,  C07D519/00

CPC classification number: C07D471/10 ,  A61K45/06 ,  C07D519/00

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof;




wherein R1 R2, R4 and X1 are defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

公开(公告)号：US20220348566A1

公开(公告)日：2022-11-03

申请号：US17716423

申请日：2022-04-08

Applicant: NOVARTIS AG

Inventor： Andreas Kordikowski ,  Yugang Liu ,  Rainer Martin Lüönd ,  Christian Markert ,  Wolfgang Miltz ,  Till Roehn ,  Carsten Spanka ,  Gebhard Thoma ,  Tian XIE

IPC: C07D413/10 ,  A61K45/06 ,  A61K31/4245 ,  A61K31/4439 ,  C07D413/14 ,  C07D471/04 ,  A61K31/436 ,  C07D401/14 ,  C07D401/12 ,  C07D257/04 ,  A61K31/41

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

公开(公告)号：US20240199593A1

公开(公告)日：2024-06-20

申请号：US18426461

申请日：2024-01-30

Applicant: NOVARTIS AG

Inventor： Andreas Kordikowski ,  Yugang Liu ,  Rainer Martin Lüönd ,  Christian Markert ,  Wolfgang Miltz ,  Till Roehn ,  Carsten Spanka ,  Gebhard Thoma ,  Tian XIE

IPC: C07D413/10 ,  A61K31/41 ,  A61K31/4245 ,  A61K31/436 ,  A61K31/4439 ,  A61K45/06 ,  C07D257/04 ,  C07D401/12 ,  C07D401/14 ,  C07D413/14 ,  C07D471/04

CPC classification number: C07D413/10 ,  A61K31/41 ,  A61K31/4245 ,  A61K31/436 ,  A61K31/4439 ,  A61K45/06 ,  C07D257/04 ,  C07D401/12 ,  C07D401/14 ,  C07D413/14 ,  C07D471/04

Abstract: The present invention provides a crystalline form of (S)-2-amino-3-(3-(4-((3-fluoro-5-(1H-pyrazol-5-yl)pyridin-2-yl)oxy)phenyl)-1H-pyrazol-1-yl)propan-1-ol, in its free form;

a method for manufacturing said crystalline form, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

公开(公告)号：US10570096B2

公开(公告)日：2020-02-25

申请号：US15778783

申请日：2016-11-24

Applicant: NOVARTIS AG

Inventor： Gebhard Thoma

IPC: C07D213/74 ,  C07D401/12 ,  A61K31/444

Abstract: The present invention describes novel diamino pyridine derivatives exhibiting JAK modulating properties. The present invention also relates to pharmaceutical compositions comprising these novel compounds, methods of using said compounds in the treatment of various diseases and disorders being susceptible to JAK modulation, and processes for preparing the compounds described hereinafter.